Literature DB >> 12470134

Immunophenotype of conjunctival melanomas: comparisons with uveal and cutaneous melanomas.

Satori Iwamoto1, Robert C Burrows, Hans E Grossniklaus, James Orcutt, Robert E Kalina, Michael Boehm, Mark A Bothwell, Rodney Schmidt.   

Abstract

OBJECTIVE: To characterize the immunophenotypic expression pattern of conjunctival melanomas, with the use of standard melanoma markers as well as microphthalmia transcription factor and p75 neurotrophin receptor.
DESIGN: Eleven conjunctival melanomas, including 1 caruncular melanoma, were immunolabeled with a panel of antibodies that included S100, tyrosinase, melan-A, HMB-45 and HMB-50 combination, microphthalmia transcription factor, and p75 neurotrophin receptor. The results were tabulated on the basis of intensity and pervasiveness of labeling and compared with a previous study of uveal melanomas.
RESULTS: Immunolabeling with S100 was at significantly higher levels in conjunctival melanomas than in uveal melanomas. Tyrosinase, HMB-45 and HMB-50 combination, melan-A, and microphthalmia transcription factor were expressed at high levels in conjunctival melanomas, whereas p75 neurotrophin receptor was not expressed.
CONCLUSIONS: Melanomas of the conjunctiva, including the caruncle, expressed S100, tyrosinase, melan-A, HMB-45 and HMB-50 combination, and microphthalmia transcription factor at high levels, suggesting that these are good markers for this melanoma subtype. Expression of S100 was significantly higher in conjunctival melanomas than in uveal melanomas. The immunophenotypic pattern of conjunctival melanomas is most similar to the epithelioid subtype of cutaneous melanomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12470134     DOI: 10.1001/archopht.120.12.1625

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  8 in total

Review 1.  Advances in the management of conjunctival melanoma.

Authors:  Gargi K Vora; Hakan Demirci; Brian Marr; Prithvi Mruthyunjaya
Journal:  Surv Ophthalmol       Date:  2016-06-16       Impact factor: 6.048

2.  Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions.

Authors:  S Keijser; G S Missotten; J M Bonfrer; D de Wolff-Rouendaal; M J Jager; R J W de Keizer
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

3.  Diagnostic utility of cytokeratin 17 immunostaining in morpheaform basal cell carcinoma and for facilitating the detection of tumor cells at the surgical margins.

Authors:  Heidi Anderson-Dockter; Todd Clark; Satori Iwamoto; Ming Lu; David Fiore; Jane K Falanga; Vincent Falanga
Journal:  Dermatol Surg       Date:  2012-06-12       Impact factor: 3.398

Review 4.  Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.

Authors:  Joel M Mor; Ludwig M Heindl
Journal:  Ocul Oncol Pathol       Date:  2016-12-08

5.  Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization.

Authors:  Shinji Ozaki; Raja Vuyyuru; Ken Kageyama; Mizue Terai; Masahiro Ohara; Hanyin Cheng; Tim Manser; Michael J Mastrangelo; Andrew E Aplin; Takami Sato
Journal:  Am J Pathol       Date:  2015-11-25       Impact factor: 4.307

6.  Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor.

Authors:  Husvinee Sundaramurthi; Sandra García-Mulero; Valentina Tonelotto; Kayleigh Slater; Simone Marcone; Josep M Piulats; Ronald William Watson; Desmond J Tobin; Lasse D Jensen; Breandán N Kennedy
Journal:  Cancers (Basel)       Date:  2022-02-03       Impact factor: 6.639

Review 7.  New Therapeutic Approaches for Conjunctival Melanoma-What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells.

Authors:  Jennifer Peil; Felix Bock; Friedemann Kiefer; Rebecca Schmidt; Ludwig M Heindl; Claus Cursiefen; Simona L Schlereth
Journal:  Int J Mol Sci       Date:  2022-01-27       Impact factor: 5.923

8.  Immunohistochemical expression of melan-A and tyrosinase in uveal melanoma.

Authors:  Bruno F Fernandes; Alexandre N Odashiro; Vinicius S Saraiva; Patrick Logan; Emilia Antecka; Miguel N Burnier
Journal:  J Carcinog       Date:  2007-04-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.